Cibinqo Shortage Update: What Patients Need to Know in 2026

If you've been struggling to fill your Cibinqo prescription, you may be wondering: is there an official shortage? The short answer is no — as of 2026, Cibinqo (abrocitinib) is not on the FDA's drug shortage list. But that doesn't mean the drug is easy to access. Here's what's actually driving the difficulty, and what patients need to know today.

Is Cibinqo in an Official FDA Shortage in 2026?

No. As of 2026, Cibinqo (abrocitinib) does not appear on the FDA's official drug shortage database. Pfizer, the manufacturer, has not issued any public notices about manufacturing disruptions or supply constraints for abrocitinib tablets. The drug is being produced and distributed normally through specialty pharmacy channels.

However, patients across the country are still experiencing delays and difficulty filling their Cibinqo prescriptions — and those experiences are real, even if they stem from different causes than a traditional drug shortage.

What Is Actually Causing Cibinqo Access Problems?

The barriers to getting Cibinqo are systemic — rooted in the specialty drug distribution and insurance authorization system — rather than supply chain failures. The main causes:

Prior authorization requirements. Virtually every insurance plan requires PA before covering Cibinqo. PA processing can take 1–3 weeks, and denials are common.

Specialty pharmacy distribution. Cibinqo is not stocked at most retail pharmacies — it must be dispensed through specialty pharmacies like Accredo, CVS Specialty, or Walgreens Specialty.

Step therapy requirements. Many insurers require patients to "fail" on less expensive treatments before approving Cibinqo, adding months to the timeline.

High cost. With no generic available, Cibinqo's retail price is approximately $7,000–$7,100 per month. Without adequate insurance or savings programs, patients simply cannot afford it.

Has Cibinqo Ever Been in an Official Shortage?

Since its FDA approval in January 2022, Cibinqo has not been listed as an official shortage on the FDA drug shortage database. Unlike medications such as ADHD drugs or certain injectable chemotherapy agents that have faced widespread manufacturing-related shortages, Cibinqo's supply from Pfizer has remained consistent. The drug is a specialty product with a smaller patient population, so traditional shortage dynamics are less likely to apply.

Why Do Some Patients Feel Like They're Experiencing a Shortage?

Even without a formal shortage, patients can still feel "shortage-like" access problems when:

Their local specialty pharmacy runs low on stock temporarily

Their insurance-preferred specialty pharmacy is backordered for that particular dosage

Shipping delays from mail-order specialty pharmacies leave them without medication for days

Prior authorization is under review or denied, and no bridge supply is arranged

37,512+ patients found their medications in stock

37K+

Find Cibinqo In Stock Today →

What Steps Should You Take Right Now?

If you're unable to get Cibinqo right now, here are the most important immediate steps:

Contact Pfizer Dermatology Patient Access at 1-833-956-3376 — they can assist with insurance navigation, copay programs, and bridge supply during PA delays.

Call your prescriber to expedite the PA — a peer-to-peer review request or appeal letter can move things forward.

Use medfinder to find which pharmacies near you can fill your Cibinqo prescription — instead of calling every specialty pharmacy yourself.

Ask your doctor about alternatives in case of extended delays — Dupixent, Rinvoq, or Adbry may be options.

How medfinder Helps Patients Find Cibinqo

When pharmacy access is the issue — not supply — medfinder can help. You tell us your medication, dosage, and zip code. We call pharmacies near you — including specialty pharmacies — to identify which ones can fill your Cibinqo prescription. Results are texted back to you quickly, saving you hours of phone calls.

Read our deeper dive on why Cibinqo is hard to find for a full breakdown of the specialty pharmacy and insurance system.